Trial Profile
The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms BeST
- 15 Nov 2018 Status changed from active, no longer recruiting to completed.
- 14 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 17 Jun 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.